Results 81 to 90 of about 5,159 (186)

Mapping Clinical Progression to Brain Atrophy in CLN2 Patients Under Cerliponase Alfa Treatment: A Prospective Neuroimaging Study

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 3, May 2026.
ABSTRACT Neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a lysosomal storage disorder, causes early childhood psychomotor regression, vision loss, seizures, and rapid progressive gray matter loss. However, the link between neurodegenerative processes induced by lysosomal pathophysiology and the clinical phenotype remains unclear.
Marvin Petersen   +12 more
wiley   +1 more source

Activation of CLN1 and CLN2 G1 cyclin gene expression by BCK2 [PDF]

open access: yes, 1995
The Saccharomyces cerevisiae CLN3 protein, a G1 cyclin, positively regulates the expression of CLN1 and CLN2, two additional G1 cyclins whose expression during late G1 is activated, in part, by the transcription factors SWI4 and SWI6.
Di Como, C. J.   +2 more
core  

Targeted re-sequencing for early diagnosis of genetic causes of childhood epilepsy: the Italian experience from the ‘beyond epilepsy’ project

open access: yesItalian Journal of Pediatrics, 2020
Background Childhood epilepsies are a heterogeneous group of conditions differing in diagnostic criteria, management, and outcome. Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) is a neurodegenerative condition caused by biallelic TPP1 ...
Elisabetta Amadori   +17 more
doaj   +1 more source

Expert‐Designed Fact Sheets and AI‐Based Analysis of Patient Symptoms to Combat Diagnostic Delays in Inherited Metabolic Diseases

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT The importance of early diagnosis of inherited metabolic diseases (IMDs) is well known, as it allows early intervention to prevent or reduce complications and improve prognosis, since many of these disorders are treatable. However, diagnosis can still be delayed, and many patients remain undiagnosed. Reducing diagnosis delays is a primary goal
Aline Cano   +108 more
wiley   +1 more source

Cln2 degroni ja promootori mõju valgu ekspressiooni tasemele [PDF]

open access: yes, 2020
Precise regulation of the cell cycle events is essential for correct DNA replication and successful cell reproduction. Progression through the cell cycle is tightly controlled over a multisite phosphorylation network.
Shmidt, Daniel
core  

The impact of Cln2 degron and Cln2 promoter on protein expression levels

open access: yes, 2021
Precise regulation of the cell cycle events is essential for correct DNA replication and successful cell reproduction. Progression through the cell cycle is tightly controlled over a multisite phosphorylation network. Phosphorylation of specific amino acids (phosphory-lation sites, or phosphosites) might either activate a protein or send it for ...
openaire   +1 more source

Epidemiology of progressive intellectual and neurological deterioration in UK children

open access: yesDevelopmental Medicine &Child Neurology, Volume 68, Issue 3, Page 418-428, March 2026.
This study of PIND in UK children was carried out via the British Paediatric Surveillance Unit from 1997 to 2024. It identified six cases of vCJD. 2367 children had other diagnoses explain their deterioration. There were 259 other diseases in the diagnosed group.
Christopher M. Verity   +3 more
wiley   +1 more source

Zur Pathogenese der spätinfantilen neuronalen Ceroidlipofuszinose (CLN2) : Beeinflussung des Energiestoffwechsels und der Proliferation an einem zellulären Modell der CLN2-Krankheit [PDF]

open access: yes, 2006
Die neuronalen Ceroid-Lipofuszinosen (NCL-Krankheiten) sind progrediente neurodegenerative Krankheiten. Gemeinsames Merkmal aller Formen ist die Entwicklung von Demenz und Amaurose sowie die intrazelluläre Speicherung von Ceroidlipofuszin.
Liersch, Julia
core  

Untargeted Metabolomics for Diagnosis, Monitoring, and Understanding the Pathophysiology of Inherited Metabolic Disorders

open access: yesJournal of Inherited Metabolic Disease, Volume 49, Issue 1, January 2026.
ABSTRACT Inherited metabolic disorders (IMDs) encompass a diverse and expanding group of rare diseases caused by genetic disruptions mainly in metabolic enzymes and transporters. Clinical diagnosis of IMDs presents significant challenges due to phenotypic heterogeneity, nonspecific symptoms, and the limited scope of current targeted biochemical assays ...
Jonathan Martens   +4 more
wiley   +1 more source

Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data.

open access: yesPLoS ONE
BackgroundThe CLN2 Clinical Rating Scale evaluates disease progression in CLN2 disease, an ultra-rare, neurodegenerative disorder with late infantile onset. To validate the Clinical Rating Scale, a comparison with the Pediatric Quality of Life Inventory (
Nicola Specchio   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy